I41 Post-marketing adverse events (AES) associated with tetrabenazine (TBZ): findings using FDA’s adverse event reporting system (FAERS)

BackgroundIn clinical trials of patients with Huntington’s disease (HD), treatment with TBZ resulted in more neuropsychiatric AEs compared to placebo, including insomnia, somnolence, anxiety, depression, and agitation.AimTo summarise post-marketing reports of AEs associated with TBZ by analysing cas...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurology, neurosurgery and psychiatry Vol. 87; no. Suppl 1; p. A73
Main Authors:	Claassen, Daniel O, Iyer, Ravi, Dimbil, Mo, Giron, Abril, De Boer, Lisa, Gandhi, Sanjay, Hoffman, Keith B
Format:	Journal Article
Language:	English
Published:	01-09-2016
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	BackgroundIn clinical trials of patients with Huntington’s disease (HD), treatment with TBZ resulted in more neuropsychiatric AEs compared to placebo, including insomnia, somnolence, anxiety, depression, and agitation.AimTo summarise post-marketing reports of AEs associated with TBZ by analysing case reports from FAERS.MethodsFAERS data for branded TBZ (Xenazine®) included case reports meeting minimal key identification field criteria: individual safety report number, patient number, drug sequence identification, and MedDRA AE term. RxFilter was used for standardisation of case report data and was applied to TBZ data to analyse AEs with relevant regulatory interest. Primary suspect counts of AEs in which TBZ is suspected as the causative agent and calculation of disproportional reporting rates were performed to identify potential safety signals.ResultsPost-marketing safety data for TBZ included many of the most frequent AEs as reported in the pivotal trial, including depression, somnolence, fatigue, fall and insomnia, indicating a consistency between these two sources. Of the AEs that were common between clinical trial and post-marketing observations, depression was most frequently reported in the post-marketing data. In clinical trials, depression was the fourth most commonly reported AE and was preceded by sedation/somnolence, insomnia and fatigue. A disproportionality analysis identified high reporting odds ratios (>2) for some neuropsychiatric AEs, indicating that there is a higher-than-expected reporting rate.ConclusionsAlthough post-marketing AE reporting is voluntary and thus a potentially more conservative estimate of safety signals compared with clinical trials, there was consistency between TBZ-associated AEs reported in the clinical trial setting and spontaneous post-marketing AE reporting. The real-world spontaneous AE reporting could be a useful data source to guide informed patient care decisions.
ISSN:	0022-3050 1468-330X
DOI:	10.1136/jnnp-2016-314597.206